Overview
- The CNIO-led experiments used a three-drug regimen targeting KRAS-driven signaling and, according to the authors, blocked pathways that typically enable resistance.
- In mouse models of pancreatic ductal adenocarcinoma, tumors disappeared and the animals remained healthy for months without notable side effects.
- The study was authored by renowned oncologist Mariano Barbacid and appears in the Proceedings of the National Academy of Sciences.
- The approach builds on a 2019 CNIO mouse study that eliminated tumors by jointly inhibiting EGFR and c‑RAF within the KRAS pathway.
- Researchers stress the results are preclinical and require replication, dose and safety work, and clinical trials before any potential use in patients.